Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 14/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.55 |
| ▸ | SIRT3 | Q9NTG7 | 6/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29100713 | 1.00 | SIRT2 (0.55) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL29100662 | 0.94 | SIRT2 (0.61) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL29100660 | 0.94 | SIRT2 (0.61) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL7904398 | 0.92 | CTSK (0.51) | CTSLCTSS | |
| SCHEMBL29750243 | 0.92 | MEN1 (0.58) | SIRT2SIRT1SIRT3MEN1ALDH1A1 | |
| SCHEMBL10389689 | 0.90 | SIRT2 (0.62) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL26896562 | 0.89 | CTSL (0.60) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL30902868 | 0.88 | CTSK (0.51) | CTSLCTSS | |
| SCHEMBL13570900 | 0.88 | SYK (0.55) | CTSLCTSSALDH1A1 | |
| SCHEMBL9819558 | 0.88 | SYK (0.55) | CTSLCTSSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375544-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | UNIV MUENCHEN TECH (DE) | 2025-12-11 | — | — | US | disclosed |
| EP-4271422-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | Technische Universität München (DE) | 2023-11-08 | — | — | EP | disclosed |
| CN-116981486-A | Dual mode radiotracer and therapeutic agent | 慕尼黑工业大学 | 2023-10-31 | — | — | CN | disclosed |
| WO-2022144467-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | Technische Universität München (DE) | 2022-07-07 | — | — | WO | disclosed |
| EP-4023250-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | Technische Universität München (DE) | 2022-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375544-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | MAN2B1, GBA1, SSTR1 | SIRT2 2417/4885SIRT1 1790/4885SIRT3 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.